CTTNBP2NL

Across TCGA pan-cancer cohorts, CTTNBP2NL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTTNBP2NL data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher CTTNBP2NL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTTNBP2NL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UVM, UCEC, and CHOL are the cancer types where CTTNBP2NL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.104	0.858	<.001	33	view →
UCEC	DFS	Median	All	0.929	0.619	.025	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTTNBP2NL–UVM (OS)

Open the UVM breakdown →